Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
OTUD6B-AS1 is a long non-coding RNA (lncRNA) transcribed from the antisense strand of the OTUD6B gene on chromosome 8q21.3 (Zheng et al., 2025 [1]). It acts as a multifaceted regulator in various human malignancies and autoimmune conditions like systemic sclerosis, where it exhibits a dual role as either an oncogene or a tumor suppressor depending on the specific tissue context (Takata et al., 2019 [2]). The primary mechanism of action for OTUD6B-AS1 is its function as a competitive endogenous RNA (ceRNA), sponging microRNAs such as miR-3171 and miR-664b-3p to modulate downstream signaling pathways, most notably the Wnt/β-catenin and PI3K/AKT/mTOR pathways (Wang et al., 2021 [3]; Kong et al., 2020 [4]). In cancers like breast and hepatocellular carcinoma, its upregulation promotes tumor growth, metastasis, and resistance to therapies like paclitaxel and cisplatin (Li et al., 2021 [5]). Conversely, in colorectal and renal cell carcinomas, it often acts as a tumor suppressor, and its downregulation is associated with poor prognosis (Wang et al., 2019 [6]). Given its significant impact on cellular processes like ferroptosis, apoptosis, and epithelial-mesenchymal transition, OTUD6B-AS1 is being investigated as both a diagnostic biomarker and a potential therapeutic target for RNA-based interventions (GeneCards [7]). Research into targeting OTUD6B-AS1 using antisense oligonucleotides (ASOs) has shown promise in preclinical models for inhibiting tumor progression and modulating immune responses (Takata et al., 2019 [2]).
Competitive endogenous RNA (ceRNA) mechanism involving microRNA sponging (e.g., miR-3171, miR-664b-3p, miR-26a-5p) to regulate downstream signaling pathways such as Wnt/β-catenin and PI3K/AKT/mTOR.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Ovarian tumor domain containing 6B antisense RNA 1 (OTUD6B-AS1) (OTUD6B-AS1).